PMID- 29122484
OWN - NLM
STAT- MEDLINE
DCOM- 20171201
LR  - 20180816
IS  - 1464-3405 (Electronic)
IS  - 0960-894X (Linking)
VI  - 27
IP  - 23
DP  - 2017 Dec 1
TI  - Delphinidin inhibits BDNF-induced migration and invasion in SKOV3 ovarian cancer 
      cells.
PG  - 5337-5343
LID - S0960-894X(17)30917-4 [pii]
LID - 10.1016/j.bmcl.2017.09.024 [doi]
AB  - Brain-derived neurotrophic factor (BDNF), the TrkB ligand, is associated with 
      aggressive malignant behavior, including migration and invasion, in tumor cells 
      and a poor prognosis in patients with various types of cancer. Delphinidin is a 
      diphenylpropane-based polyphenolic ring structure-harboring compound, which 
      exhibits a wide range of pharmacological activities, anti-tumor, anti-oxidant, 
      anti-inflammatory, anti-angiogenic and anti-mutagenic activity. However, the 
      possible role of delphinidin in the cancer migration and invasion is unclear. We 
      investigated the suppressive effect of delphinidin on the cancer migration and 
      invasion. Thus, we found that BDNF enhanced cancer migration and invasion in 
      SKOV3 ovarian cancer cell. To exam the inhibitory role of delphinidin in SKOV3 
      ovarian cancer migration and invasion, we investigated the use of delphinidin as 
      inhibitors of BDNF-induced motility and invasiveness in SKOV3 ovarian cancer 
      cells in vitro. Here, we found that delphinidin prominently inhibited the 
      BDNF-induced increase in cell migration and invasion of SKOV3 ovarian cancer 
      cells. Furthermore, delphinidin remarkably inhibited BDNF-stimulated expression 
      of MMP-2 and MMP-9. Also, delphinidin antagonized the phosphorylation of Akt and 
      nuclear translocation of NF-kappaB permitted by the BDNF in SKOV3 ovarian cancer 
      cells. Taken together, our findings provide new evidence that delphinidin 
      suppressed the BDNF-induced ovarian cancer migration and invasion through 
      decreasing of Akt activation.
CI  - Copyright (c) 2017 Elsevier Ltd. All rights reserved.
FAU - Lim, Won-Chul
AU  - Lim WC
AD  - Laboratory of Molecular Oncology, Cheil General Hospital & Women's Healthcare 
      Center, College of Medicine, Dankook University, Seoul, South Korea.
FAU - Kim, Hyunhee
AU  - Kim H
AD  - Laboratory of Molecular Oncology, Cheil General Hospital & Women's Healthcare 
      Center, College of Medicine, Dankook University, Seoul, South Korea.
FAU - Kim, Young-Joo
AU  - Kim YJ
AD  - Natural Products Research Center, Korea Institute of Science and Technology, 
      Gangneung, Gangwon-do, South Korea.
FAU - Park, Seung-Ho
AU  - Park SH
AD  - Department of Biomedical Sciences, Asan Medical Center, University of Ulsan 
      College of Medicine, Seoul, South Korea; Department of Pharmacology, University 
      of Ulsan College of Medicine, Seoul, South Korea.
FAU - Song, Ji-Hye
AU  - Song JH
AD  - Department of Biomedical Sciences, Asan Medical Center, University of Ulsan 
      College of Medicine, Seoul, South Korea; Department of Pharmacology, University 
      of Ulsan College of Medicine, Seoul, South Korea.
FAU - Lee, Ki Heon
AU  - Lee KH
AD  - Department of Obstetrics and Gynecology, Cheil General Hospital & Women's 
      Healthcare Center, College of Medicine, Dankook University, Seoul, South Korea.
FAU - Lee, In Ho
AU  - Lee IH
AD  - Department of Obstetrics and Gynecology, Cheil General Hospital & Women's 
      Healthcare Center, College of Medicine, Dankook University, Seoul, South Korea.
FAU - Lee, Yoo-Kyung
AU  - Lee YK
AD  - Department of Obstetrics and Gynecology, Cheil General Hospital & Women's 
      Healthcare Center, College of Medicine, Dankook University, Seoul, South Korea.
FAU - So, Kyeong A
AU  - So KA
AD  - Department of Obstetrics and Gynecology, Cheil General Hospital & Women's 
      Healthcare Center, College of Medicine, Dankook University, Seoul, South Korea.
FAU - Choi, Kyung-Chul
AU  - Choi KC
AD  - Department of Biomedical Sciences, Asan Medical Center, University of Ulsan 
      College of Medicine, Seoul, South Korea; Department of Pharmacology, University 
      of Ulsan College of Medicine, Seoul, South Korea. Electronic address: 
      choikc75@amc.seoul.kr.
FAU - Ko, Hyeonseok
AU  - Ko H
AD  - Laboratory of Molecular Oncology, Cheil General Hospital & Women's Healthcare 
      Center, College of Medicine, Dankook University, Seoul, South Korea. Electronic 
      address: drug9054@naver.com.
LA  - eng
PT  - Journal Article
DEP - 20170918
PL  - England
TA  - Bioorg Med Chem Lett
JT  - Bioorganic & medicinal chemistry letters
JID - 9107377
RN  - 0 (Anthocyanins)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 7171WSG8A2 (BDNF protein, human)
RN  - EM6MD4AEHE (delphinidin)
SB  - IM
MH  - Anthocyanins/chemical synthesis/chemistry/*pharmacology
MH  - Antineoplastic Agents/chemical synthesis/chemistry/*pharmacology
MH  - Brain-Derived Neurotrophic Factor/*antagonists & inhibitors/metabolism
MH  - Cell Line, Tumor
MH  - Cell Movement/drug effects
MH  - Cell Proliferation/drug effects
MH  - Cell Survival/drug effects
MH  - Dose-Response Relationship, Drug
MH  - Drug Screening Assays, Antitumor
MH  - Female
MH  - Humans
MH  - Molecular Structure
MH  - Ovarian Neoplasms/*drug therapy/metabolism/pathology
MH  - Structure-Activity Relationship
OTO - NOTNLM
OT  - Akt
OT  - Brain-derived neurotrophic factor (BDNF)
OT  - Delphinidin
OT  - Invasion
OT  - Migration
OT  - Ovarian cancer
EDAT- 2017/11/11 06:00
MHDA- 2017/12/02 06:00
CRDT- 2017/11/11 06:00
PHST- 2017/07/04 00:00 [received]
PHST- 2017/08/28 00:00 [revised]
PHST- 2017/09/11 00:00 [accepted]
PHST- 2017/11/11 06:00 [pubmed]
PHST- 2017/12/02 06:00 [medline]
PHST- 2017/11/11 06:00 [entrez]
AID - S0960-894X(17)30917-4 [pii]
AID - 10.1016/j.bmcl.2017.09.024 [doi]
PST - ppublish
SO  - Bioorg Med Chem Lett. 2017 Dec 1;27(23):5337-5343. doi: 
      10.1016/j.bmcl.2017.09.024. Epub 2017 Sep 18.